Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Insulin sudelidec, also known by its code name INS068 and brand name Shudi Insulin Injection, is a novel, soluble, long-acting insulin analog developed by Jiangsu HengRui Medicine Co., Ltd. It functions as an insulin receptor agonist, designed to provide stable and prolonged blood glucose-lowering effects. This pharmaceutical drug is intended for the treatment of both type 1 and type 2 diabetes mellitus, aiming to cover basal insulin requirements. Clinical trials have shown its efficacy and safety profiles to be comparable to existing long-acting insulin analogs like insulin glargine and insulin degludec.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on insulin sudelidec.